Cargando…

Metabolic derangements of skeletal muscle from a murine model of glioma cachexia

BACKGROUND: Cachexia is a complex metabolic disorder and muscle atrophy syndrome, impacting 80% patients with advanced cancers. Malignant glioma is considered to be one of the deadliest human cancers, accounting for about 60% of all primary brain tumors. However, cachexia symptoms induced by glioma...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Pengfei, Shao, Wei, Huang, Caihua, Wu, Chang-Jer, Jiang, Bin, Lin, Donghai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330447/
https://www.ncbi.nlm.nih.gov/pubmed/30635036
http://dx.doi.org/10.1186/s13395-018-0188-4
_version_ 1783386975939592192
author Cui, Pengfei
Shao, Wei
Huang, Caihua
Wu, Chang-Jer
Jiang, Bin
Lin, Donghai
author_facet Cui, Pengfei
Shao, Wei
Huang, Caihua
Wu, Chang-Jer
Jiang, Bin
Lin, Donghai
author_sort Cui, Pengfei
collection PubMed
description BACKGROUND: Cachexia is a complex metabolic disorder and muscle atrophy syndrome, impacting 80% patients with advanced cancers. Malignant glioma is considered to be one of the deadliest human cancers, accounting for about 60% of all primary brain tumors. However, cachexia symptoms induced by glioma have received little attention. This work aims to explore skeletal muscle atrophy in orthotopic glioma murine models. METHODS: BALB/c nude mice were orthotopicly implanted with normal glial (HEB) and glioma (WHO II CHG5 and WHO IV U87) cells. Cachexia symptoms of mice were depicted by phenotypic, histopathologic, physiological, and biochemical analyses. Muscle atrophy-related proteins were examined by western blot, and the involved signaling pathways were analyzed. NMR-based metabolomic analysis was applied to profile metabolic derangements in the skeletal muscle, including multivariate statistical analysis, characteristic metabolite identification, and metabolic pathway analysis. RESULTS: Compared with controls, mice implanted with glioma cells exhibit typical cachexia symptoms, indicating a high correlation with the malignant grades of glioma. U87 mice develop cachexia much earlier and more severe than CHG5 mice. The glioma-bearing mice showed significantly decreased skeletal muscle mass and strength, which were associated with suppressed AKT, activated AMPK, FOXO, Atrogin1, and LC3. Interestingly, expressions of MuRF1, MyoD1, and eIF3f were not significantly changed. Consistently, metabolomic analyses elucidate pronounced metabolic derangements in cachectic gastrocnemius relative to controls. Glucose, glycerol, and 3-hydroxybutyrate were remarkably downregulated, whereas glutamate, arginine, leucine, and isoleucine were upregulated in cachectic gastrocnemius. Furthermore, U87 mice showed more characteristic metabolites and more disturbed metabolic pathways including glucose and lipid metabolism, protein catabolism, anabolism, and citric acid cycle anaplerotic. CONCLUSIONS: This study demonstrates for the first time that the orthotopic glioma murine model developed here exhibits high fidelity of cachexia manifestations in two malignant grades of glioma. Signaling pathway analysis in combination with metabolomic analysis provides significant insights into the complex pathophysiology of glioma cachexia and expands understanding of the molecular mechanisms underlying muscle atrophy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13395-018-0188-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6330447
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63304472019-01-16 Metabolic derangements of skeletal muscle from a murine model of glioma cachexia Cui, Pengfei Shao, Wei Huang, Caihua Wu, Chang-Jer Jiang, Bin Lin, Donghai Skelet Muscle Research BACKGROUND: Cachexia is a complex metabolic disorder and muscle atrophy syndrome, impacting 80% patients with advanced cancers. Malignant glioma is considered to be one of the deadliest human cancers, accounting for about 60% of all primary brain tumors. However, cachexia symptoms induced by glioma have received little attention. This work aims to explore skeletal muscle atrophy in orthotopic glioma murine models. METHODS: BALB/c nude mice were orthotopicly implanted with normal glial (HEB) and glioma (WHO II CHG5 and WHO IV U87) cells. Cachexia symptoms of mice were depicted by phenotypic, histopathologic, physiological, and biochemical analyses. Muscle atrophy-related proteins were examined by western blot, and the involved signaling pathways were analyzed. NMR-based metabolomic analysis was applied to profile metabolic derangements in the skeletal muscle, including multivariate statistical analysis, characteristic metabolite identification, and metabolic pathway analysis. RESULTS: Compared with controls, mice implanted with glioma cells exhibit typical cachexia symptoms, indicating a high correlation with the malignant grades of glioma. U87 mice develop cachexia much earlier and more severe than CHG5 mice. The glioma-bearing mice showed significantly decreased skeletal muscle mass and strength, which were associated with suppressed AKT, activated AMPK, FOXO, Atrogin1, and LC3. Interestingly, expressions of MuRF1, MyoD1, and eIF3f were not significantly changed. Consistently, metabolomic analyses elucidate pronounced metabolic derangements in cachectic gastrocnemius relative to controls. Glucose, glycerol, and 3-hydroxybutyrate were remarkably downregulated, whereas glutamate, arginine, leucine, and isoleucine were upregulated in cachectic gastrocnemius. Furthermore, U87 mice showed more characteristic metabolites and more disturbed metabolic pathways including glucose and lipid metabolism, protein catabolism, anabolism, and citric acid cycle anaplerotic. CONCLUSIONS: This study demonstrates for the first time that the orthotopic glioma murine model developed here exhibits high fidelity of cachexia manifestations in two malignant grades of glioma. Signaling pathway analysis in combination with metabolomic analysis provides significant insights into the complex pathophysiology of glioma cachexia and expands understanding of the molecular mechanisms underlying muscle atrophy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13395-018-0188-4) contains supplementary material, which is available to authorized users. BioMed Central 2019-01-11 /pmc/articles/PMC6330447/ /pubmed/30635036 http://dx.doi.org/10.1186/s13395-018-0188-4 Text en © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Cui, Pengfei
Shao, Wei
Huang, Caihua
Wu, Chang-Jer
Jiang, Bin
Lin, Donghai
Metabolic derangements of skeletal muscle from a murine model of glioma cachexia
title Metabolic derangements of skeletal muscle from a murine model of glioma cachexia
title_full Metabolic derangements of skeletal muscle from a murine model of glioma cachexia
title_fullStr Metabolic derangements of skeletal muscle from a murine model of glioma cachexia
title_full_unstemmed Metabolic derangements of skeletal muscle from a murine model of glioma cachexia
title_short Metabolic derangements of skeletal muscle from a murine model of glioma cachexia
title_sort metabolic derangements of skeletal muscle from a murine model of glioma cachexia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330447/
https://www.ncbi.nlm.nih.gov/pubmed/30635036
http://dx.doi.org/10.1186/s13395-018-0188-4
work_keys_str_mv AT cuipengfei metabolicderangementsofskeletalmusclefromamurinemodelofgliomacachexia
AT shaowei metabolicderangementsofskeletalmusclefromamurinemodelofgliomacachexia
AT huangcaihua metabolicderangementsofskeletalmusclefromamurinemodelofgliomacachexia
AT wuchangjer metabolicderangementsofskeletalmusclefromamurinemodelofgliomacachexia
AT jiangbin metabolicderangementsofskeletalmusclefromamurinemodelofgliomacachexia
AT lindonghai metabolicderangementsofskeletalmusclefromamurinemodelofgliomacachexia